Skip to main content
. Author manuscript; available in PMC: 2023 Jun 29.
Published in final edited form as: N Engl J Med. 2022 Sep 29;387(13):1196–1206. doi: 10.1056/NEJMoa2209900

Figure 2. Loss of GPRC5D on Immunohistochemical Analysis at Relapse after MCARH109 Infusion.

Figure 2.

GPRC5D and CD138 immunohistochemical analysis of plasmacytoma tissue samples from Patient 15 at baseline and at relapse after MCARH109 infusion (dose level, 150×106 CAR T cells) shows loss of GPRC5D expression at the time of relapse. The patient had a best response of stringent complete response.